Abstract
ADP-ribosylation factor-like 4c (ARL4C) is identified as a small GTP-binding protein, which is expressed by Wnt and EGF signaling and plays an important role in tubulogenesis of cultured cells and the ureters. ARL4C is little expressed in adult tissues, but it is highly expressed in lung cancer and colorectal cancer and shown to represent a molecular target for cancer therapy based on siRNA experiments. This study revealed that ARL4C is highly expressed in primary hepatocellular carcinoma (HCC) tumors and colorectal cancer liver metastases, and that ARL4C expression is associated with poor prognosis for these cancers. Chemically modified antisense oligonucleotides (ASO) against ARL4C effectively reduced ARL4C expression in both HCC and colorectal cancer cells and inhibited proliferation and migration of these cancer cells in vitro. ARL4C ASOs decreased the PIK3CD mRNA levels and inhibited the activity of AKT in HCC cells, suggesting that the downstream signaling of ARL4C in HCC cells is different from that in lung and colon cancer cells. In addition, subcutaneous injection of ARL4C ASO was effective in reducing the growth of primary HCC and metastatic colorectal cancer in the liver of immunodeficient mice. ARL4C ASO accumulated in cancer cells more efficiently than the surrounding normal cells in the liver and decreased ARL4C expression in the tumor. These results suggest that ARL4C ASO represents a novel targeted nucleic acid medicine for the treatment of primary and metastatic liver cancers.
| Original language | English |
|---|---|
| Pages (from-to) | 602-612 |
| Number of pages | 11 |
| Journal | Molecular Cancer Therapeutics |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Chemically modified antisense oligonucleotide against ARL4C inhibits primary and metastatic liver tumor growth. / Harada, Takeshi; Matsumoto, Shinji; Hirota, Suguru; Kimura, Hirokazu; Fujii, Shinsuke; Kasahara, Yuuya; Gon, Hidetoshi; Yoshida, Toshihiko; Itoh, Tomoo; Haraguchi, Naotsugu; Mizushima, Tsunekazu; Noda, Takehiro; Eguchi, Hidetoshi; Nojima, Satoshi; Morii, Eiichi; Fukumoto, Takumi; Obika, Satoshi; Kikuchi, Akira.
In: Molecular Cancer Therapeutics, Vol. 18, No. 3, 01.03.2019, p. 602-612.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chemically modified antisense oligonucleotide against ARL4C inhibits primary and metastatic liver tumor growth
AU - Harada, Takeshi
AU - Matsumoto, Shinji
AU - Hirota, Suguru
AU - Kimura, Hirokazu
AU - Fujii, Shinsuke
AU - Kasahara, Yuuya
AU - Gon, Hidetoshi
AU - Yoshida, Toshihiko
AU - Itoh, Tomoo
AU - Haraguchi, Naotsugu
AU - Mizushima, Tsunekazu
AU - Noda, Takehiro
AU - Eguchi, Hidetoshi
AU - Nojima, Satoshi
AU - Morii, Eiichi
AU - Fukumoto, Takumi
AU - Obika, Satoshi
AU - Kikuchi, Akira
PY - 2019/3/1
Y1 - 2019/3/1
N2 - ADP-ribosylation factor-like 4c (ARL4C) is identified as a small GTP-binding protein, which is expressed by Wnt and EGF signaling and plays an important role in tubulogenesis of cultured cells and the ureters. ARL4C is little expressed in adult tissues, but it is highly expressed in lung cancer and colorectal cancer and shown to represent a molecular target for cancer therapy based on siRNA experiments. This study revealed that ARL4C is highly expressed in primary hepatocellular carcinoma (HCC) tumors and colorectal cancer liver metastases, and that ARL4C expression is associated with poor prognosis for these cancers. Chemically modified antisense oligonucleotides (ASO) against ARL4C effectively reduced ARL4C expression in both HCC and colorectal cancer cells and inhibited proliferation and migration of these cancer cells in vitro. ARL4C ASOs decreased the PIK3CD mRNA levels and inhibited the activity of AKT in HCC cells, suggesting that the downstream signaling of ARL4C in HCC cells is different from that in lung and colon cancer cells. In addition, subcutaneous injection of ARL4C ASO was effective in reducing the growth of primary HCC and metastatic colorectal cancer in the liver of immunodeficient mice. ARL4C ASO accumulated in cancer cells more efficiently than the surrounding normal cells in the liver and decreased ARL4C expression in the tumor. These results suggest that ARL4C ASO represents a novel targeted nucleic acid medicine for the treatment of primary and metastatic liver cancers.
AB - ADP-ribosylation factor-like 4c (ARL4C) is identified as a small GTP-binding protein, which is expressed by Wnt and EGF signaling and plays an important role in tubulogenesis of cultured cells and the ureters. ARL4C is little expressed in adult tissues, but it is highly expressed in lung cancer and colorectal cancer and shown to represent a molecular target for cancer therapy based on siRNA experiments. This study revealed that ARL4C is highly expressed in primary hepatocellular carcinoma (HCC) tumors and colorectal cancer liver metastases, and that ARL4C expression is associated with poor prognosis for these cancers. Chemically modified antisense oligonucleotides (ASO) against ARL4C effectively reduced ARL4C expression in both HCC and colorectal cancer cells and inhibited proliferation and migration of these cancer cells in vitro. ARL4C ASOs decreased the PIK3CD mRNA levels and inhibited the activity of AKT in HCC cells, suggesting that the downstream signaling of ARL4C in HCC cells is different from that in lung and colon cancer cells. In addition, subcutaneous injection of ARL4C ASO was effective in reducing the growth of primary HCC and metastatic colorectal cancer in the liver of immunodeficient mice. ARL4C ASO accumulated in cancer cells more efficiently than the surrounding normal cells in the liver and decreased ARL4C expression in the tumor. These results suggest that ARL4C ASO represents a novel targeted nucleic acid medicine for the treatment of primary and metastatic liver cancers.
UR - http://www.scopus.com/inward/record.url?scp=85065235435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065235435&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-18-0824
DO - 10.1158/1535-7163.MCT-18-0824
M3 - Article
VL - 18
SP - 602
EP - 612
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 3
ER -